SnapShot: Brain-targeting anti-obesity medications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40043693.
- Also identified by DOI 10.1016/j.cmet.2025.02.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Advances in the understanding of homeostatic regulation of body weight and the neurobiology of appetite, combined with innovations in medicinal chemistry, have paved the way for safe and effective weight loss medications. Long-acting GLP-1 receptor agonists have revolutionized obesity treatment, and, together with emerging GLP-1-based multi-agonists and combination therapies, offer significant potential to combat cardiometabolic diseases and a range of other chronic health challenges. To view this SnapShot, open or download the PDF.
Medical subject headings
- Anti-Obesity Agents
- Obesity
- Brain